Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2024.02.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von E T Zemanick und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: edith.zemanick@childrenscolorado.org. Hauptthemen laut MEDLINE: Cystic Fibrosis, Sweat, Chlorides, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: Sweat chloride (SC) concentrations in people with cystic fibrosis (PwCF) reflect relative CF transmembrane conductance regulator (CFTR) protein function, the primary CF defect. Populations with greater SC concentrations tend to have lesser CFTR function and more severe disease courses. CFTR modulator treatment can improve CFTR function within specific CF genotypes and is commonly associated with reduced SC concentration. However, SC concentrations do not necessarily fall to concentrations seen in the unaffected population, suggesting potential for better CFTR treatment outcomes. We characterized post-modulator SC concentration variability among CHEC-SC study participants by genotype and modulator. METHODS: PwCF receiving commercially approved modulators for ≥90 days were enrolled for a single SC measurement. Clinical data were obtained from chart review and the CF Foundation Patient Registry (CFFPR). Variability of post-modulator SC concentrations was assessed by cumulative SC concentration frequencies. RESULTS: Post-modulator SC concentrations (n = 3787) were collected from 3131 PwCF; most (n = 1769, 47 %) were collected after elexacaftor/tezacaftor/ivacaftor (ETI) treatment. Modulator use was associated with lower SC distributions, with post-ETI concentrations the lowest on average. Most post-ETI SC concentrations were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: edith.zemanick@childrenscolorado.org.
- Seattle Children's Hospital, Seattle, WA, United States.
- Seattle Children's Hospital, Seattle, WA, United States; University of Washington, Seattle, WA, United States.
- Case Western Reserve University School of Medicine, Cleveland, OH, United States.
- Children's Hospital of Philadelphia, Philadelphia, PA, United States.
- Case Western Reserve University School of Medicine, Cleveland, OH, United States; Rainbow Babies and Children's Hospital, Cleveland, OH, United States.
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- Cystic Fibrosis Foundation
- NIH
- National Center for Advancing Translational Sciences
Zitieren
APA
Zemanick, E. T., Emerman, I., McCreary, M., Mayer-Hamblett, N., Warden, M. N., Odem-Davis, K., VanDevanter, D. R., Ren, C. L., Young, J., Konstan, M. W., & CHEC-SC Study Group (2024). Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.02.001
Vancouver
Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, Warden MN, Odem-Davis K, et al. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.02.001
BibTeX
@article{Zemanick2024,
author = {Zemanick, E T and Emerman, I and McCreary, M and Mayer-Hamblett, N and Warden, M N and Odem-Davis, K and VanDevanter, D R and Ren, C L and Young, J and Konstan, M W and CHEC-SC Study Group, CHEC-SC Study Group},
title = {Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2024.02.001}
}
EUVIMED